Alnylam Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference Transcript
Salveen Richter, one of the biotechnology analysts at Goldman Sachs, and we're pleased to have Alnylam with us. And with us we have Barry Greene, President of Alnylam.
Questions & Answers
So Barry, maybe to start. Back in 2015, you announced Alnylam 2020, your initiative to kind of -- to end that year with 3 marketed products, 10 clinical programs and 4 in late stages of development across 3 verticals. So as we sit here, you've got 1.5 years to go, where are you faring on that?
Yes. So first of all, thanks for having us, and appreciate Goldman for having us in this conference, incredible venue. Thank you for being here.
So yes, you're exactly right. We felt, starting actually in 2011, that it was important for Alnylam to provide multiyear guidance. We, of course, are a platform technology. We've
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
